KennethB.GordonMD

PubMed

• Bimekizumab for the treatment of psoriasis.
  Molly Thapar, Milan Patel, Kenneth Gordon> ;Immunotherapy. 2024 Apr 1
• Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
  Bruce Strober, Andrew Blauvelt, Richard B Warren, Kim A Papp, April W Armstrong, Kenneth B Gordon, Akimichi Morita, Andrew F Alexis, Mark Lebwohl, Peter Foley, Renata ...> ;Journal of the European Academy of Dermatology and Venereology. 2024 Mar 7
• Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary: A Secondary Analysis of a Randomized Clinical Trial.
  Papp, K., Strober, B., Zhuo, J., Becker, B., Zhong, Y., Beaumont, J., Pham, T., Kisa, R., Napoli, A., Banerjee, S., Gordon, K., Armstrong, A.> ;JAMA Dermatology. 2024 Feb 1
• Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
  Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, David Rosmarin, Mark Lebwohl, Luke Peterson, Cynthia Madden, Dirk de Cuyper, Owen Davies, Diamant ...> ;The British Journal of Dermatology. 2024 Mar 15
• 1 citations
  Next Generation PDE4 Inhibitors that Selectively Target PDE4B/D Subtypes: A Narrative Review.
  Andrew Blauvelt, Richard G Langley, Kenneth B Gordon, Jonathan I Silverberg, Kilian Eyerich, Morten O A Sommer, Jakob Felding, Richard B Warren> ;Dermatology and Therapy. 2023 Dec 1
• 11 citations
  Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, pl...
  Akimichi Morita, Bruce Strober, A David Burden, Siew Eng Choon, Milan J Anadkat, Slaheddine Marrakchi, Tsen-Fang Tsai, Kenneth B Gordon, Diamant Thaçi, Min Zheng, Na H...> ;Lancet. 2023 Oct 28
• Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply.
  Singla, S., Putman, M., Liew, J., Gordon, K.> ;The Lancet. Rheumatology. 2023 Jun 1
• 2 citations
  Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
  Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon, Peter Foley, Phoebe Rich, Carle Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Ku...> ;Immunotherapy. 2023 Aug 1
• 11 citations
  Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study.
  Singla, S., Putman, M., Liew, J., Gordon, K.> ;The Lancet. Rheumatology. 2023 Apr 1
• 6 citations
  Anti-IL 23 biologics for the treatment of plaque psoriasis.
  Alan Vu, Caden Ulschmid, Kenneth B Gordon> ;Expert Opinion on Biological Therapy. 2022 Dec 1
• 1 citations
  Deucravacitinib in moderate-to-severe psoriasis.
  Alan Vu, Victoria Maloney, Kenneth B Gordon> ;Immunotherapy. 2022 Nov 1
• 66 citations
  Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3...
  Bruce Strober, Diamant Thaçi, Howard Sofen, Leon Kircik, Kenneth B Gordon, Peter Foley, Phoebe Rich, Carle Paul, Jerry Bagel, Elizabeth Colston, John Throup, Sudeep Ku...> ;Journal of the American Academy of Dermatology. 2023 Jan 1
• 9 citations
  Super-response to guselkumab treatment in patients with moderate-to-severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Invest...
  K Reich, K B Gordon, B Strober, R G Langley, M Miller, Y-W Yang, Y-K Shen, Y You, Y Zhu, P Foley, A Blauvelt> ;Journal of the European Academy of Dermatology and Venereology. 2022 Dec 1
• 17 citations
  Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
  Kenneth B Gordon, Richard G Langley, Richard B Warren, Yukari Okubo, Linda Stein Gold, Joseph F Merola, Luke Peterson, Krista Wixted, Nancy Cross, Delphine Deherder, D...> ;JAMA Dermatology. 2022 Jul 1
• 26 citations
  Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
  Diamant Thaçi, Bruce Strober, Kenneth B Gordon, Peter Foley, Melinda Gooderham, Akimichi Morita, Kim A Papp, Lluís Puig, M Alan Menter, Matthew J Colombo, Yedid Elbez,...> ;Dermatology and Therapy. 2022 Feb 1
• 8 citations
  Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study.
  Jeffrey J Crowley, Richard G Langley, Kenneth B Gordon, Andreas Pinter, Laura K Ferris, Simone Rubant, Huzefa Photowala, Zhenyi Xue, Tianshuang Wu, Tianyu Zhan, Stefan...> ;Dermatology and Therapy. 2022 Feb 1
• 33 citations
  Molecular and clinical effects of selective TYK2 inhibition with deucravacitinib in psoriasis.
  Ian M. Catlett, Yanhua Hu, Lu Gao, Subhashis Banerjee, Kenneth B. Gordon, James G. Krueger> ;The Journal of Allergy and Clinical Immunology. 2021 Nov 9
• 33 citations
  Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
  Kenneth B. Gordon, Mark Lebwohl, Kim Papp, Hervé Bachelez, Jashin J. Wu, Richard G. Langley, Andrew Blauvelt, B Kaplan, M Shah, Y Zhao, R Sinvhal, Kristian Reich> ;The British Journal of Dermatology. 2021 Oct 15
• 25 citations
  Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: resul...
  Kristian Reich, Kenneth B. Gordon, Bruce Strober, April W. Armstrong, Megan Miller, Yaung-Kaung Shen, Yin You, Chenglong Han, Y. W. Yang, Peter Foley, Cem Griffiths> ;The British Journal of Dermatology. 2021 Jun 9
• 6 citations
  Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque...
  Andrew Blauvelt, Kenneth B. Gordon, Patricia C. Lee, Jerry Bagel, Howard Sofen, Benjamin Lockshin, Ahmed M. Soliman, Ziqian Geng, Tianyu Zhan, Gabriela Alperovich, Lin...> ;The Journal of Dermatological Treatment. 2021 May 5
• 96 citations
  Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
  Kenneth B. Gordon, Peter Foley, James G. Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi, And...> ;Lancet. 2021 Feb 6
• 104 citations
  Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, acti...
  Kristian Reich, Kim A. Papp, Andrew Blauvelt, Richard G. Langley, April W. Armstrong, Richard B. Warren, Kenneth B. Gordon, Joseph F. Merola, Yukari Okubo, Cynthia Mad...> ;Lancet. 2021 Feb 6
• 103 citations
  Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures.
  Craig A. Elmets, Neil J. Korman, Elizabeth Farley Prater, Emily B. Wong, Reena N. Rupani, Dario Kivelevitch, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Dawn Ma...> ;Journal of the American Academy of Dermatology. 2021 Feb 1
• 15 citations
  Characterization of Patients with Psoriasis in Challenging-to-Treat Body Areas in the Corrona Psoriasis Registry.
  Kristina Callis Duffin, Marc A Mason, Kenneth B. Gordon, Ryan W. Harrison, Margaux M. Crabtree, Adriana Guana, Rebecca Germino, Mark Lebwohl> ;Dermatology. 2021 Jan 1
• 24 citations
  Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe Psoriasis: The UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials.
  Matthias Augustin, Jo Lambert, Carla Zema, Elizabeth H Z Thompson, Min Yang, Eric Q. Wu, Viviana Garcia-Horton, Ziqian Geng, Joaquin Mario Valdes, Avani Joshi, Kenneth...> ;JAMA Dermatology. 2020 Dec 1
• Join now to see all